Phaarmasia

Which are the latest news on Phaarmasia?

Should I buy, sell or hold Phaarmasia Ltd?

Why is Phaarmasia Ltd falling/rising?

As of 14-Jul, Phaarmasia Ltd's stock price is at 86.76, down 4.4%, with a significant decline of 23.04% year-to-date. The stock has consistently underperformed against the Sensex and shows a bearish trend, indicated by lower delivery volumes and trading below several moving averages.

As of 14-Jul, Phaarmasia Ltd's stock price is falling, currently at 86.76, which reflects a change of -3.99 or -4.4%. The stock has been underperforming significantly, with a decline of -12.13% over the past week, compared to a mere -1.44% drop in the Sensex. Over the last month, the stock has decreased by -17.17%, while the Sensex has gained +2.02%. Year-to-date, Phaarmasia Ltd has seen a decline of -23.04%, contrasting with the Sensex's -9.58%. <BR><BR>The stock has been on a consecutive downward trend for the last four days, resulting in a total drop of -12.32% during this period. Today's trading performance indicates that the stock has underperformed its sector by -4.89%. Additionally, the stock reached an intraday low of Rs 86.51, reflecting a decline of -4.67%. <BR><BR>Investor participation appears to be waning, as evidenced by a -30.19% decrease in delivery volume on 13 July compared to the five-day average. Although the stock is trading above its 200-day moving average, it remains below the 5-day, 20-day, 50-day, and 100-day moving averages, indicating a bearish trend. Overall, these factors contribute to the current decline in Phaarmasia Ltd's stock price.

How big is Phaarmasia?

As of 10th June, Phaarmasia Ltd has a market capitalization of 75.00 Cr, with recent net sales of 47.20 Cr and a net profit of 17.58 Cr.

As of 10th June, Phaarmasia Ltd has a market capitalization of 75.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Phaarmasia reported Net Sales of 47.20 Cr and a Net Profit of 17.58 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 8.74 Cr and Total Assets valued at 21.47 Cr.

Who are in the management team of Phaarmasia?

The management team of Phaarmasia includes Vinay Ramakant Sapte (Director), Maneesh R Sapte (Non Executive Director), Y N Bhaskara Rao (Whole-time Director), Rashmi V Sapte (Director), Pravin M. Hegde (Independent Director), Ajit G Jamkhandikar (Independent Director), and Urvashi Bhatia (Company Secretary & Compliance Officer).

The management team of Phaarmasia includes the following individuals:<BR><BR>1. Vinay Ramakant Sapte - Director<BR>2. Maneesh R Sapte - Non Executive Director<BR>3. Y N Bhaskara Rao - Whole-time Director<BR>4. Rashmi V Sapte - Director<BR>5. Pravin M. Hegde - Independent Director<BR>6. Ajit G Jamkhandikar - Independent Director<BR>7. Urvashi Bhatia - Company Secretary & Compliance Officer<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the Phaarmasia?

Phaarmasia's peers include Bharat Immunolog, Bacil Pharma, Source Natural, Vineet Laborator, Sunil Healthcare, Zenith Drugs, Vilin Bio Med, Ajooni Biotech, JFL Life, and Onyx Biotec. Phaarmasia has the highest 1-year return at 227.71%, significantly outperforming its peers, while JFL Life shows excellent management and growth metrics.

Peers: The peers of Phaarmasia are Bharat Immunolog, Bacil Pharma, Source Natural, Vineet Laborator, Sunil Healthcare, Zenith Drugs, Vilin Bio Med, Ajooni Biotech, JFL Life, and Onyx Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at JFL Life, while Average management risk is found at Phaarmasia and the rest. Below Average management risk is noted for Bharat Immunolog, Bacil Pharma, Vineet Laborator, Sunil Healthcare, Zenith Drugs, Vilin Bio Med, Ajooni Biotech, and Onyx Biotec. Growth is Excellent at JFL Life, Average at Phaarmasia, Vilin Bio Med, and Ajooni Biotech, and Below Average at Bharat Immunolog, Source Natural, Vineet Laborator, Sunil Healthcare, Zenith Drugs, and Onyx Biotec. Capital Structure is Good at Source Natural and JFL Life, while Below Average is seen at Bharat Immunolog, Phaarmasia, Vineet Laborator, Sunil Healthcare, Zenith Drugs, Vilin Bio Med, and Onyx Biotec, and does not qualify for Bacil Pharma.<BR><BR>Return Snapshot: Phaarmasia has the highest 1-year return at 227.71%, while Bharat Immunolog has the lowest at -34.23%. Phaarmasia's return significantly outperforms all peers. Additionally, Source Natural, Sunil Healthcare, and Zenith Drugs have negative six-month returns.

What does Phaarmasia do?

Phaarmasia Ltd is a micro-cap manufacturing company specializing in hormonal products, particularly oral contraceptives and iron combipacks. As of March 2026, it reported net sales of 8 Cr and a net profit of -1 Cr, with a market cap of INR 75 Cr.

Overview:<BR>Phaarmasia Ltd is a manufacturing company specializing in hormonal products, specifically oral contraceptive tablets and combipacks with iron tablets, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>History:<BR>Incorporated in 1981, Phaarmasia Ltd established its manufacturing unit, Unit-II, in 1993-94. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 8 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 75 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.04 <BR>Return on Equity: 19.11% <BR>Price to Book: 6.42 <BR><BR>Contact Details:<BR>Address: 16 Phase III, I D A Jeedimetla Hyderabad Telangana : 500055 <BR>Tel: 91-40-23095002/23095690 <BR>Email: phaarmasia@yahoo.com / phaarmasia@gma <BR>Website: http://www.phaarmasia.com

Are Phaarmasia Ltd latest results good or bad?

Phaarmasia Ltd's latest results show significant quarterly improvements, with a 544.44% increase in net profit and 179.09% revenue growth. However, long-term challenges, including a declining five-year operating profit CAGR and high stock valuation, suggest caution for potential investors.

Phaarmasia Ltd's latest results present a mixed picture. On one hand, the company reported significant improvements in its Q2 FY26 performance, with net profit rising to ₹1.74 crore, a remarkable increase of 544.44% quarter-on-quarter, and revenue growth of 179.09% year-on-year, reaching ₹16.55 crore. The operating margin also improved to 9.73%, up from just 1.16% in the previous quarter.<BR><BR>However, these positive results come against a backdrop of long-term challenges. The company has a weak five-year operating profit CAGR of -12.60% and an average return on equity (ROE) of only 1.45%, raising concerns about its long-term viability. Additionally, despite the recent spike in revenue, the overall financial performance for the fiscal year ending March 2025 showed a decline in net sales by 20% compared to the previous year, and the company recorded an operating loss.<BR><BR>Moreover, Phaarmasia's stock has exhibited extreme volatility, and its high valuation at 91 times trailing earnings complicates the investment outlook. The lack of institutional interest, with only 0.06% participation, further highlights skepticism about the company's sustainability.<BR><BR>In summary, while the latest quarterly results show a strong recovery, the underlying structural issues and inconsistent performance suggest caution for potential investors.

When is the next results date for Phaarmasia Ltd?

The next results date for Phaarmasia Ltd is February 6, 2026.

The next results date for Phaarmasia Ltd is scheduled for February 6, 2026.

Is Phaarmasia overvalued or undervalued?

As of November 21, 2025, Phaarmasia is considered overvalued with a high PE ratio of 42.96 and lagging stock performance, compared to peers like Sun Pharma and Cipla, which have lower valuation metrics.

As of 21 November 2025, Phaarmasia's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its high PE ratio of 42.96, an EV to EBIT ratio of 33.08, and a Price to Book Value of 3.12. In comparison to its peers, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla is valued attractively with a PE of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Given these metrics, Phaarmasia appears overvalued in the current market environment. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of only 1.20% compared to the Sensex's 9.08%, further reinforcing the assessment of overvaluation.

How has been the historical performance of Phaarmasia?

Phaarmasia's historical performance has shown a decline in net sales and profitability, with net sales dropping from 30.59 Cr in March 2024 to 24.37 Cr in March 2025, and operating profit worsening from -0.17 Cr to -1.26 Cr during the same period. Total assets and liabilities also decreased, leading to a reduced book value per share from 8.87 to 6.58.

Answer:<BR>The historical performance of Phaarmasia shows a fluctuating trend in net sales and profitability over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Phaarmasia's net sales peaked at 30.59 Cr in March 2024 but fell to 24.37 Cr by March 2025. The total operating income followed a similar pattern, decreasing from 30.59 Cr in March 2024 to 24.37 Cr in March 2025. The company's total expenditure, excluding depreciation, also decreased from 31.42 Cr in March 2024 to 26.38 Cr in March 2025, yet the operating profit (PBDIT) remained negative, worsening from -0.17 Cr in March 2024 to -1.26 Cr in March 2025. Profit before tax also declined, moving from -0.55 Cr in March 2024 to -1.60 Cr in March 2025, while profit after tax showed a similar trend, dropping from -0.52 Cr to -1.59 Cr in the same period. The company's total assets decreased from 31.37 Cr in March 2024 to 21.47 Cr in March 2025, with total liabilities also declining from 31.37 Cr to 21.47 Cr. The book value per share adjusted down from 8.87 in March 2024 to 6.58 in March 2025, reflecting the overall downward trend in financial performance.

Who are the top shareholders of the Phaarmasia?

The top shareholder of Phaarmasia is Maneesh Pharmaceuticals Limited, with a 44.22% stake. Individual investors, led by Madhavi Pradeep Save at 1.73%, collectively own 26.18%, while there are no mutual funds or foreign institutional investors involved.

The top shareholders of Phaarmasia include Maneesh Pharmaceuticals Limited, which holds the largest stake at 44.22%. The majority of the company's shares are held by promoters, and there are no pledged promoter holdings. In terms of public shareholders, Madhavi Pradeep Save is the highest individual investor, holding 1.73%. Additionally, individual investors collectively own 26.18% of the company. There are currently no mutual funds or foreign institutional investors holding shares in Phaarmasia.

What is the technical trend for Phaarmasia?

As of June 5, 2025, Phaarmasia's trend is mildly bearish, with mixed signals from indicators like MACD and Bollinger Bands, suggesting a cautious approach due to prevailing bearish sentiment in the longer term.

As of 5 June 2025, the technical trend for Phaarmasia has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The MACD on a weekly basis is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The Bollinger Bands are mildly bearish on both weekly and monthly time frames, suggesting a potential continuation of the downward trend. Moving averages on a daily basis are bearish, reinforcing the negative outlook. The KST shows a mildly bullish signal weekly but is bearish monthly, while Dow Theory indicates a mildly bearish trend weekly and mildly bullish monthly. Overall, the mixed signals across different indicators suggest a cautious approach, with the bearish sentiment prevailing in the longer term.

Has Phaarmasia declared dividend?

No Dividend History Available